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A B S T R A C T
Objective: We investigated the associations between serum levels of glycated albumin (GA) or
hemoglobin A1c (HbA1c) and the presence of coronary artery disease (CAD) in patients who underwent
coronary computed tomography angiography (CTA).
Methods and results: The study consisted of 244 consecutive patients who underwent CTA and in whom
we could measure the levels of both GA and HbA1c. Any narrowing of the normal contrast-enhanced
lumen to >50% that could be identiﬁed in multiplanar reconstructions or cross-sectional images by CTA
was deﬁned as signiﬁcant stenosis in CAD. We divided the patients into two groups: CAD group (n = 72)
and non-CAD group (n = 172), as assessed by CTA. The CAD group showed signiﬁcantly higher GA and
HbA1c than the non-CAD group. GA and HbA1c showed a positive correlation (r = 0.551, p < 0.0001). A
multivariate logistic regression analysis was performed to examine the associations between the
presence of CAD and age, gender, body mass index, and coronary risk factors (hypertension,
dyslipidemia, and smoking), in addition to GA and HbA1c. Age [odds ratio (OR): 1.04, p = 0.02], gender
(OR: 2.84 p = 0.01), hypertension (OR: 3.20, p = 0.01), and GA (OR: 1.16, p = 0.03) were identiﬁed
as signiﬁcant independent variables that predicted the presence of CAD. In particular, GA (OR: 1.30,
p = 0.02) was the only predictor of the presence of CAD in the diabetes mellitus group by a multivariate
logistic regression analysis. We deﬁned the cut-off value of GA for the prediction of CAD in patients with
diabetes as 17.9% (sensitivity 0.639, speciﬁcity 0.639) by a receiver-operating characteristic curve
analysis.
Conclusion: GA may be superior to HbA1c as a marker for evaluating the presence of CAD.
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Serum levels of hemoglobin A1c (HbA1c) are strongly
correlated with average blood glucose (BG) levels [1,2], whereas
serum levels of glycated albumin (GA) reﬂect postcibal BG levels
[2]. Some previous studies have indicated that impaired glucose
tolerance makes a greater contribution to the risk of coronary
artery disease (CAD) than impaired fasting glucose [3,4]. In
addition, patients with impaired glucose tolerance who are treated
with acarbose show a signiﬁcant reduction in the risk of CAD [5].* Corresponding author at: Department of Cardiology, Fukuoka University School
of Medicine, 7-45-1, Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan.
Tel.: +81 92 801 1011x3366; fax: +81 92 865 2692.
E-mail address: miuras@cis.fukuoka-u.ac.jp (S.-i. Miura).
http://dx.doi.org/10.1016/j.jjcc.2014.07.006
0914-5087/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsAlthough HbA1c, fasting BG levels, and mean BG concentrations
are not correlated with oxidative stress, the mean amplitude of
glycemic excursions and postcibal BG levels are positively
correlated with oxidative stress, which indicates that the target
of therapy should be not only HbA1c, but also acute glucose
ﬂuctuation in patients with type 2 diabetes mellitus (DM) [6]. In
addition, GA is more strongly correlated with microvascular
conditions than HbA1c [7], and an increase in serum GA is also
associated with the presence and severity of CAD in type 2 DM [8].
These reports indicated that GA may be superior to HbA1c as a
predictor of CAD. Therefore, we investigated the associations
between serum levels of GA or HbA1c and the presence of CAD in
patients who underwent coronary computed tomography angiog-
raphy (CTA), and considered whether GA is more useful than
HbA1c for predicting the presence of CAD. reserved.
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Study subjects
Two hundred and forty-four consecutive subjects who were
clinically suspected to have CAD were enrolled. All subjects
underwent CTA and their GA and HbA1c levels were measured.
Patients in whom we could not evaluate coronary stenosis due to
severe calciﬁcation, or who had acute coronary syndrome,
Kawasaki disease, or Marfan syndrome were excluded. The
protocol in this study was approved by the ethics committee of
Fukuoka University Hospital, and all subjects gave their written
informed consent to participate.
Evaluation of coronary stenosis using CTA
We evaluated coronary stenosis using CTA as previously
described [9]. Brieﬂy, all patients were scanned by 64-multi-
detector row computed tomography (MDCT) on an Aquilion 64
(Toshiba, Tokyo, Japan). The use of b-blocker and nitroglycerin
before scanning was left to the physician’s discretion. A 70-ml
bolus of contrast medium (Omnipaque, 350 mg iodine/ml, Daiichi
Sankyo Co. Ltd., Tokyo, Japan) was injected at a ﬂow rate of 3.6 ml/
s, and followed by 35 ml of contrast agent and 30 ml of saline
solution, each at a ﬂow rate of 1.8 ml/s, with a dual injector. The
region of interest was placed within the ascending aorta, and theTable 1
Characteristics of patients in all, CAD and non-CAD groups.
Variables All (n = 244) 
Age (years) 66 (59–72) 
Male (%) 57 
BMI (kg/m2) 24  4 
Smoking (%) 48 
FH (%) 28 
HTN (%) 75 
SBP (mmHg) 133 (123–146) 
DBP (mmHg) 77  12 
DL (%) 77 
LDL-C (mg/dl) 110  30 
HDL-C (mg/dl) 49 (43–60) 
TG (mg/dl) 120 (87–162) 
TC (mg/dl) 195  36 
HU (%) 18 
UA (mg/dl) 6.0 (5.0–6.0) 
DM (%) 30 
Random BG (mg/dl) 101 (93–115) 
HbA1c (%) 5.9 (5.6–6.4) 
GA (%) 15.6 (14.3–17.1) 
CKD (%) 31 
eGFR (ml/min/1.73 m2) 68  15 
PAD (%) 2 
Medications
ARB/ACE-I (%) 42 
CCB (%) 38 
BB (%) 14 
DU (%) 12 
Statin (%) 35 
Insulin (%) 4 
SU (%) 8 
Biguanide (%) 9 
DPP4-I 10 
Continuous variables are expressed as mean  SD. When continuous variables did no
interquartile range.
CAD, coronary artery disease; BMI, body mass index; FH, family history; HTN, hypertension
low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, trigly
BG, blood glucose; HbA1c, glycosylated hemoglobin A1c; GA, glycated albumin; CKD, chron
disease; ARB, angiotensin II receptor blocker; ACE-I, angiotensin-converting enzyme inh
DPP4-I, dipeptidyl-peptidase 4 inhibitor.
* p < 0.05 vs. non-CAD group.
** p < 0.01 vs. non-CAD group.scan was started when the CT density reached 100 Hounsﬁeld
Units higher than the baseline CT density. The scan was performed
between the tracheal bifurcation and the diaphragm with the
following parameters: collimation width 0.5 mm, rotation speed
0.4 s/rotation, tube voltage 135 kV, and effective tube current
360 mA. All segments were assessed according to the 15-segment
American Heart Association coronary artery model [10]. Overall,
15 coronary artery segments were assessed in all patients. Any
narrowing of the normal contrast-enhanced lumen to >50% that
could be identiﬁed in multiplanar reconstructions or cross-
sectional images was deﬁned as signiﬁcant stenosis in CAD.
Evaluation of CAD risk factors
Age, gender, body mass index (BMI), systolic blood pressure
(SBP), diastolic blood pressure (DBP), serum levels of total
cholesterol (TC), triglycerides (TG), high-density lipoprotein
cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C),
uric acid (UA), GA, HbA1c and BG, smoking status (current vs.
nonsmoker), family history [myocardial infarction (MI), angina
pectoris, or sudden death], and medication use were evaluated as
risk factors for CAD in all patients.
BMI was calculated as weight (kg)/height (m2). BP was
determined as the mean of two measurements obtained in an
ofﬁce setting by the conventional cuff method using a mercury
sphygmomanometer after at least 5 min of rest. The characteristicsCAD (n = 72) Non-CAD (n = 172)
68 (61–74)* 64 (57–71)
67* 53
24  4 24  4
50 48
26 29
89** 69
135 (123–147) 132 (122–145)
76  13 77  12
79 76
108  27 111  32
47 (40–56)** 51 (44–62)
128 (93–188) 114 (80–154)
189  33 198  36
18 18
5.0 (4.0–6.0) 6.0 (5.0–7.0)
50** 21
112 (96–143)** 100 (93–108)
6.3 (5.8–7.2)** 5.8 (5.6–6.2)
16.7 (15.3–19.0)** 15.3 (14.0–16.9)
30 33
69  15 68  15
3 2
50 38
50* 33
14 15
11 12
44* 31
4 4
17** 5
17** 6
15 8
t show a normal distribution, the variables are expressed as a median value and
; SBP, systolic blood pressure; DBP, diastolic blood pressure; DL, dyslipidemia; LDL-C,
ceride; TC, total cholesterol; HU, hyperuricemia; UA, uric acid; DM, diabetes mellitus;
ic kidney disease; eGFR, estimated glomerular ﬁltration rate; PAD, peripheral arterial
ibitor; CCB, calcium channel blocker; BB, b-blocker; DU, diuretic; SU, sulfonylurea;
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dyslipidemia (DL), DM, and history of smoking were obtained from
medical records. Patients who had a current SBP 140 mmHg and/
or DBP 90 mmHg or who were receiving antihypertensive
therapy were considered to have HTN. Patients with LDL-C
140 mg/dl, TG 150 mg/dl, and/or HDL-C <40 mg/dl, or who
were receiving lipid-lowering therapy were considered to have DL
[11]. Patients with random BG 200 mg, fasting BG 126 mg,
HbA1c 6.5% or who were taking a glucose-lowering drug were
considered to have DM. Hyperuricemia (HU) was deﬁned as a
serum UA level of 7.0 mg/dl or the administration of UA-lowering
drugs.
Statistical analysis
The statistical analysis was performed using SAS software,
version 9.4 (SAS Institute, Cary, NC, USA) at Fukuoka University.
Continuous variables are shown as the mean  standard deviation.
Categorical and continuous variables were compared between the
groups by a chi-square analysis and t-test, respectively. When
continuous variables did not show a normal distribution expressed as
a median value and interquartile range, we performed a Wilcoxon
rank-sum test. The Spearman rank correlation coefﬁcient was used to
evaluate associations between the groups. We used a multiple logistic
regression analysis for the multivariate analysis to evaluate
independent predictors of CAD and selected age, gender, BMI, andTable 2
Characteristics of patients with DM in all, CAD and non-CAD groups.
Variables All (n = 72) 
Age (years) 66  9 
Male (%) 69 
BMI (kg/m2) 25  4 
Smoking (%) 61 
FH (%) 18 
HTN (%) 88 
SBP (mmHg) 141 (126–150) 
DBP (mmHg) 79  13 
DL (%) 79 
LDL-C (mg/dl) 103  27 
HDL-C (mg/dl) 49 (42–56) 
TG (mg/dl) 119 (96–179) 
TC (mg/dl) 184  31 
HU (%) 13 
UA (mg/dl) 5.0 (5.0–6.0) 
DM (%) 100 
Random BG (mg/dl) 128 (104–150) 
HbA1c (%) 6.9 (6.5–7.6) 
GA (%) 18.0 (16.2–20.9) 
CKD (%) 38 
eGFR (ml/min/1.73 m2) 67  16 
PAD (%) 3 
Medications
ARB/ACE-I (%) 47 
CCB (%) 39 
BB (%) 11 
DU (%) 14 
Statin (%) 43 
Insulin (%) 13 
SU (%) 28 
Biguanide (%) 31 
DPP4-I (%) 35 
Continuous variables are expressed as mean SD. When continuous variables did not
interquartile range.
CAD, coronary artery disease; BMI, body mass index; FH, family history; HTN, h
dyslipidemia; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipopr
uric acid; DM, diabetes mellitus; BG, blood glucose; HbA1c, glycosylated hemoglo
glomerular ﬁltration rate; PAD, peripheral arterial disease; ARB, angiotensin II rec
channel blocker; BB, b-blocker; DU, diuretic; SU, sulfonylurea; DPP4-I, dipeptidyl-p
* p < 0.05 vs. non-CAD.coronary risk factors (smoking, HTN, DL) in addition to GA and HbA1c
as independent variables. A receiver-operating characteristic (ROC)
curve analysis was used to determine the cut-off values of GA and
HbA1c to distinguish between patients with and without CAD at the
highest possible sensitivity and speciﬁcity levels. A value of p < 0.05
was considered signiﬁcant.
Results
Patient characteristics
Table 1 shows the patient characteristics in all patients and
in the CAD and non-CAD groups. The CAD group showed a
signiﬁcantly higher age, percentage of males, prevalence of HTN
and DM, BG, HbA1c, GA, and use of calcium channel blocker (CCB),
statin, sulfonylurea (SU), and biguanide, and a signiﬁcantly lower
level of HDL-C than the non-CAD group. As shown in Table 2, we
divided the patients with DM (n = 72) into two groups: CAD
(n = 36) and non-CAD (n = 36). The CAD group showed a
signiﬁcantly higher GA level. However, there were no signiﬁcant
differences in HbA1c or the use of glucose-lowering drugs between
the two groups. Next, we divided the patients without DM
(n = 172) into two groups: CAD (n = 36) and non-CAD (n = 136)
(Table 3). The CAD group was signiﬁcantly older and had a higher
incidence of HTN and use of CCB, and a signiﬁcantly lower level ofCAD (n = 36) Non-CAD (n = 36)
67  9 65  10
72 67
25  3 25  5
58 64
22 14
92 83
142 (123–151) 140 (127–148)
77  14 80  12
83 75
106  24 99  30
48 (45–53) 49 (41–59)
137 (109–189) 109 (93–145)
188  30 18031
11 15
5.2 (4.4–6.1) 6.0 (5.0–7.0)
100 100
139 (113–164) 115 (101–140)
7.2 (6.6–7.7) 6.8 (6.4–7.3)
18.5 (16.6–21.8)* 16.8 (16.0–19.1)
28 44
71  17 65  14
6 0
56 39
47 31
6 17
11 17
50 36
8 17
33 22
33 28
31 39
 show a normal distribution, the variables are expressed as a median value and
ypertension; SBP, systolic blood pressure; DBP, diastolic blood pressure; DL,
otein cholesterol; TG, triglyceride; TC, total cholesterol; HU, hyperuricemia; UA,
bin A1c; GA, glycated albumin; CKD, chronic kidney disease; eGFR, estimated
eptor blocker; ACE-I, angiotensin-converting enzyme inhibitor; CCB, calcium
eptidase 4 inhibitor.
Table 3
Characteristics of patients without DM in all, CAD and non-CAD groups.
Variables All (n = 172) CAD (n = 36) Non-CAD (n = 136)
Age (years) 65 (58–72) 69 (61–75)* 64 (56–72)
Male (%) 52 61 49
BMI (kg/m2) 23 (21–26) 24 (21–26) 23 (21–26)
Smoking (%) 43 42 43
FH (%) 32 31 33
HTN (%) 70 86* 65
SBP (mmHg) 131 (122–143) 134 (124–139) 131 (120–144)
DBP (mmHg) 76  12 74  12 76  12
DL (%) 76 75 77
LDL-C (mg/dl) 113  35 111  30 114  31
HDL-C (mg/dl) 50 (43–62) 45 (27–56)** 51 (45–63)
TG (mg/dl) 122 (80–160) 126 (88–180) 119 (79–155)
TC (mg/dl) 200  43 191  37 202  36
HU (%) 20 26 18
UA (mg/dl) 6.0 (4.0–7.0) 6.0 (4.0–7.0) 6.0 (4.5–6.0)
DM (%) 0 0 0
Random BG (mg/dl) 98 (92–104) 99 (93–112) 98 (92–103)
HbAlc (%) 5.7 (5.5–6.0) 5.8 (5.6–6.0) 5.7 (5.5–5.9)
GA (%) 14.9 (13.8–16.5) 15.5 (14.4–16.9) 14.8 (13.7–16.3)
CKD (%) 27 25 29
eGFR (ml/min/1.73 m2) 68  15 67  12 69  16
PAD (%) 2 0 2
Medications
ARB/ACE-I (%) 40 44 38
CCB (%) 37 53* 33
BB (%) 16 22 14
DU (%) 11 11 11
Statin (%) 31 39 29
Continuous variables are expressed as mean SD. When continuous variables did not show a normal distribution, the variables are expressed as a median value and
interquartile range.
CAD, coronary artery disease; BMI, body mass index; FH, family history; HTN, hypertension; SBP, systolic blood pressure; DBP, diastolic blood pressure; DL,
dyslipidemia; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglyceride; TC, total cholesterol; HU, hyperuricemia; UA,
uric acid; DM, diabetes mellitus; BG, blood glucose; HbA1c, glycosylated hemoglobin A1c; GA, glycated albumin; CKD, chronic kidney disease; eGFR, estimated
glomerular ﬁltration rate; PAD, peripheral arterial disease; ARB, angiotensin II receptor blocker; ACE-I, angiotensin-converting enzyme inhibitor; CCB, calcium
channel blocker; BB, b-blocker; DU, diuretic; SU, sulfonylurea; DPP4-I, dipeptidyl-peptidase 4 inhibitor.
* p < 0.05 vs. non-CAD.
** p < 0.01 vs. non-CAD.
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differences in HbA1c or GA between the groups.
Relationships between GA or HbA1c and other factors
HbA1c and GA showed a signiﬁcant positive correlation
(Fig. 1A). Since GA showed a negative correlation with BMI [12],
we examined the correlations between GA and BMI or visceral fat
area. However, neither factor was signiﬁcantly correlated with GA
(BMI, r = 0.025, p = 0.692; visceral fat area, r = 0.017, p = 0.786).H
bA
1c
 (%
) 
r=0.551 
p<0.0001
r
p
 (%)
A
ge
 (y
.o
) 
A. B.
Fig. 1. Association between GA and HbA1c (A). Associations between age and GA (B) or theOn the other hand, GA showed a positive correlation with age
(Fig. 1B). A ratio of GA to HbA1c (GA/HbA1c), but not HbA1c
alone (r = 0.035, p = 0.577), showed a similar signiﬁcant correlation
(Fig. 1C).
Predictors of the presence of CAD in all patients and in the DM and
non-DM groups
Next, we analyzed the predictors of the presence of CAD in all
patients using independent variables by a logistic regression=0.249
<0.0001
r=0.286
p<0.0001
 (%)
A
ge
 (y
.o
) 
C.
 ratio of GA to HbA1c (GA/HbA1c) (C). GA, glycated albumin; HbA1c, hemoglobin A1c.
  OR(95%Cl)     p value 
Age    1.04 (1.01 - 1.08) 0.02
Gender  2.84 (1.28 – 6.28)    0.01
BMI    1.01 (0.93 - 1.10)     0.80
HTN 3.20 (1.29 – 7.95)    0.01 
DL  1.62 (0.76 – 3.50)    0.21
Smoking 0.63 (0.29 - 1.33)  0.22
HbA1c   1.27 (0.88 - 1.83)  0.20
GA  1.16 (1.01 - 1.32)    0.03
0.1 1 10 
Fig. 2. Logistic regression analysis for the presence of coronary artery disease in all patients using independent variables. BMI, body mass index; HTN, hypertension; DL,
dyslipidemia; HbA1c, hemoglobin A1c; GA, glycated albumin.
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(smoking, HTN, DL), GA, and HbA1c as independent variables. CAD
was independently associated with GA, in addition to age, gender,
and HTN. We also examined the predictors of the presence of CAD
in patients with or without DM using the same independent
variables by a logistic regression analysis (Figs. 3 and 4). GA was
the only predictor of the presence of CAD in the DM group. In the
non-DM group, age and gender were associated with the presence
of CAD.
Cut-off values of GA and HbA1c for the diagnosis of CAD in
the DM group
A ROC curve analysis in the DM group showed that the area
under the curve for GA (0.644) was greater than that for HbA1c
(0.594) (Fig. 5). The cut-off levels of GA and HbA1c that gave the
greatest sensitivity and speciﬁcity for the diagnosis of CAD in the
DM group were 17.9% (sensitivity 0.639, speciﬁcity 0.639) and 6.9%
(sensitivity 0.667, speciﬁcity 0.611), respectively.
Discussion
In this study, we determined whether GA is more useful than
HbA1c as a marker of the presence of CAD. As a result, we found  OR(95%Cl)       
Age    1.02 (0.96 - 1.09) 0.47
Gender  2.08 (0.46 – 9.49) 0.15
BMI   0.94 (0.82 - 1.08)     0.39
HTN 3.79 (0.60 – 23.91) 0.16 
DL  3.31 (0.75 – 14.56) 0. 11
smoking   0.69 (0.17 – 2.88) 0.61
HbA1c   0.95 (0.56 - 1.61)    0.85
GA  1.30 (1.04 - 1.62)    0.02
0.1  
p value 
Fig. 3. Logistic regression analysis for the presence of coronary artery disease in patient
hypertension; DL, dyslipidemia; HbA1c, hemoglobin A1c; GA, glycated albumin.that age, gender, HTN, and GA level were independent predictors
of the presence of CAD in all patients. Age, gender, and HTN are
well-known essential risk factors for CAD. Although GA was not a
signiﬁcant predictor in the non-DM group, age and gender were
independent predictors of the presence of CAD. As expected, GA
was the only independent predictor of the presence of CAD in the
DM group. This result indicated that GA may be superior to HbA1c
as a marker for evaluating the presence of CAD in patients with DM.
Since the half-time of serum albumin is shorter than that of
erythrocytes, GA reﬂects glycemic control over a short period in
comparison with HbA1c [13,14]. Thus, GA can be generally used for
effective decision-making after starting or changing medications,
and GA has also been reported to be useful for glycemic control in
pregnant patients and patients undergoing dialysis [15,16]. It is
generally known that GA and HbA1c show a positive correlation, as
seen in this study (Fig. 1A). There is an issue of whether GA is a
better predictor of CAD than HbA1c, although there is a signiﬁcant
positive correlation between GA and HbA1c. Generally, HbA1c
shows a good correlation with mean BG levels [1,2], whereas GA is
more closely related to postcibal BG levels [2]. Selvin et al.
previously reported that GA is a more useful predictor for the
presence of microangiopathy than HbA1c [7]. It is difﬁcult to
analyze postcibal BG precisely in outpatients at every visit,
whereas the measurement of GA is easy and not inﬂuenced by1 10  100 
s with diabetes mellitus using independent variables. BMI, body mass index; HTN,
  OR(95%Cl)       
Age    1.06 (1.01 - 1.11) 0.02
Gender  3.14 (1.18 – 8.31)    0.02
BMI   1.05 (0.93 - 1.19)     0.41
HTN  2.47 (0.84 – 7.27)     0.10 
DL  1.01 (0.39 – 2.62)  0.99
smoking   0.57 (0.22 - 1.47)     0.25
HbA1c   2.43 (0.68 – 8.75)   0.17
GA  0.99 (0.79 - 1.23)     0.91
0.1 1  10 
p value 
Fig. 4. Logistic regression analysis for the presence of coronary artery disease in patients without diabetes mellitus using independent variables. BMI, body mass index; HTN,
hypertension; DL, dyslipidemia; HbA1c, hemoglobin A1c; GA, glycated albumin.
K. Norimatsu et al. / Journal of Cardiology 65 (2015) 487–493492meals. Sakuma et al. reported that HbA1c correlated most closely
with the average fasting BG over the previous 4 weeks and that GA
correlated most closely with the average 2-h postcibal BG after
breakfast over the previous 4 weeks [17]. GA is more closely
related to glycemic ﬂuctuation and excursion than HbA1c in
diabetic patients with poor glycemic control using a continuous
glucose-monitoring system [18]. Moreover, postcibal hyperglyce-
mia contributes more to cardiovascular events and the risk of
death than fasting hyperglycemia [3–5]. The ACCORD and
ADVANCE trials indicated that strict glycemic control as assessed
by HbA1c did not prevent cardiovascular events [19,20]. These
reports may explain why GA was a useful predictor for the
presence of CAD in this study.
Another important observation in this study was that GA and
GA/HbA1c, but not HbA1c, showed a positive correlation with age.
GA/HbA1c and age have been reported to have a positive
correlation [21]. In older subjects who show a decreased capacity
of skeletal muscle, the metabolism of glucose after a meal is
reduced, as is the additional secretion of insulin. Since postcibal BGFig. 5. Receiver-operating characteristic curve analysis for (A) glycated albumin (GA) and
with diabetes mellitus.tends to be higher than fasting BG in older subjects [22], and since
GA levels reﬂect postcibal BG levels, GA levels reﬂect the state of
older subjects more precisely than HbA1c.
The cut-off levels of GA and HbA1c for the diagnosis of CAD in
the DM group were 17.9% and 6.9%, respectively. The cut-off level
of HbA1c (6.9%) does not contradict the target value of HbA1c <7.0
(prevention of diabetic complications) according to the Japan
Diabetes Society. It is possible that glycemic control that aims to
achieve GA <17.9% may be effective for the prevention of
cardiovascular events.
Study limitations
This study has several important limitations. First, the sample
size was relatively small, which limited our ability to determine
signiﬁcance. A large-scale prospective study will be needed to
prove the utility of GA-targeting therapy. Second, MDCT is not a
gold standard for the evaluation of CAD, although studies have
shown that both its sensitivity and speciﬁcity were approximately (B) hemoglobin A1c (HbA1c) for the presence of coronary artery disease in patients
K. Norimatsu et al. / Journal of Cardiology 65 (2015) 487–493 49395% of those for invasive coronary angiography for the identiﬁca-
tion of signiﬁcant coronary stenosis [23,24]. Third, in the case of
CTA in the morning, the patients did not eat breakfast. For
examinations in the afternoon, they ate breakfast and did not eat
lunch. Since we performed blood collection just before CTA, we
could not measure fasting BS in all patients.
Conclusion
In this study, we showed that GA may be superior to HbA1c as a
marker for evaluating the presence of CAD. In particular, GA was
identiﬁed as the only signiﬁcant independent variable for
predicting the presence of CAD in the DM group. GA target
therapy may be more effective for reducing the complications of
arterial sclerosis than HbA1c target therapy.
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